# Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

> **NCT04716634** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 84 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT04716634
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-19
- **Primary completion:** 2024-02-22
- **Final completion:** 2024-02-22
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04716634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04716634, "Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04716634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*